A New Pill, GMRx2, Shows Better Results Than Standard Blood Pressure Treatments
A new once-a-day pill called **GMRx2** has demonstrated better results than standard treatments for high blood pressure. This innovative medication was tested in Nigeria as part of the **VERONICA-Nigeria trial**, led by The George Institute for Global Health. The study’s findings were recently shared at the **European Society of Cardiology Congress 2024** and published in the **Journal of the American Medical Association (JAMA)**.
### What is GMRx2?
GMRx2 combines small amounts of three common blood pressure drugs—**telmisartan, amlodipine, and indapamide**—into a single pill. Unlike the typical practice in Nigeria, where treatment starts with one drug and additional medications are added gradually, GMRx2 uses all three medications from the beginning.
### Study Results: Lower Blood Pressure and Faster Control
After six months, participants taking GMRx2 experienced a larger drop in systolic blood pressure (the top number) compared to those receiving standard treatment:
– **GMRx2 group:** 31 mmHg drop
– **Standard treatment group:** 26 mmHg drop
Although the 5.8 mmHg difference might seem small, research indicates that every 5 mmHg decrease in blood pressure reduces the risk of serious complications such as heart attacks or strokes by 10%.
Moreover, GMRx2 worked faster. After just one month, **81%** of participants taking GMRx2 had their blood pressure under control, versus **55%** in the standard care group. By six months, the control rates were 82% for GMRx2 and 72% for the standard treatment.
### Safety and Expert Opinions
Importantly, both treatments were safe, with no participants dropping out due to side effects. Professor Dike Ojji, lead researcher from the University of Abuja, emphasized that GMRx2 made a significant difference even when usual care met current medical guidelines.
This is particularly relevant in low-income countries, where fewer than 25% of individuals receiving treatment achieve blood pressure control. Even in wealthier nations, only about 50% to 70% reach their target blood pressure levels.
### The Global Impact of High Blood Pressure
High blood pressure is a major global health problem, affecting more than 1 billion adults worldwide. Two-thirds of these individuals live in low- or middle-income countries. It is the leading cause of death globally, contributing to over 10 million deaths annually.
The success of GMRx2 offers hope for improved treatment options—especially in regions where heart disease poses a significant threat.
### About George Medicines and Next Steps
GMRx2 was developed by **George Medicines**, a company dedicated to advancing heart health. They have recently submitted a request for approval to the **U.S. Food and Drug Administration (FDA)**.
Professor Anthony Rodgers from The George Institute commented that this combination pill has the potential to help millions and reduce the strain on healthcare systems worldwide. The study suggests that such combination therapies could assist countries in meeting their blood pressure control targets.
### Conclusion
In summary, GMRx2 may represent a breakthrough in high blood pressure treatment. It is simple, effective, and could save many lives by lowering the risk of heart disease and stroke.
—
**If you are interested in learning more, here are some related studies on high blood pressure:**
– ARBs vs. ACE inhibitors for blood pressure management
– How blood pressure response to exercise can predict future heart disease
– The importance of daily food choices for blood pressure and heart health
– Potential side effects of common blood pressure medications
Stay informed and take control of your heart health!
https://knowridge.com/2025/10/new-triple-action-pill-offers-much-better-blood-pressure-treatment/